- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05732194
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers
March 2, 2023 updated by: Intra-Cellular Therapies, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ITI-333 in Healthy Subjects
The study will be conducted as a single-center, randomized, double-blind, placebo-controlled, ascending dose study in up to 4 sequential cohorts of healthy subjects.
Each cohort will enroll 8 subjects: 6 subjects will receive ITI-333 and 2 subjects will receive placebo once daily for 14 days.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
32
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33014-3616
- Recruiting
- Clinical Site 1
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
- Healthy male and female subjects between 18 and 45 years old (inclusive);
- BMI inclusive of 18-32 kg/m2 at screening and a minimum weight of 50 kg;
- Willingness to remain in the clinic for the inpatient portion of the study and return for follow-up visit(s) as required by protocol and as deemed necessary by the Investigator.
Key Exclusion Criteria:
- Clinically significant abnormality within 2 years of Screening that in the Investigator's opinion may place the subject at risk or interfere with study outcome variables; this includes, but is not limited to, history of or current cardiac, hepatic, renal, neurologic, GI, pulmonary, endocrinologic, hematologic, or immunologic disease or history of malignancy;
- Clinically significant abnormal findings in vital sign assessments, including blood oxygen saturation (SpO2) < 96% and respiratory rate < 12 breaths per min;
- History of psychiatric condition that in the Investigator's opinion may be detrimental to participation in the study;
- CRP, ESR, or fibrinogen that are above normal reference ranges at Screening or Day 1.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1: 0.75 mg ITI-333 or placebo once daily for 14 days
|
Matching placebo
ITI-333 oral solution
|
Experimental: Cohort 2: 1.5 mg ITI-333 or placebo once daily for 14 days
|
Matching placebo
ITI-333 oral solution
|
Experimental: Cohort 3: 3 mg ITI-333 or placebo once daily for 14 days
|
Matching placebo
ITI-333 oral solution
|
Experimental: Cohort 4: 6 mg ITI-333 or placebo once daily for 14 days
|
Matching placebo
ITI-333 oral solution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of subjects with treatment-emergent adverse events
Time Frame: up to 30 days after last dose
|
up to 30 days after last dose
|
|
Pharmacokinetics: AUC0-tau
Time Frame: predose and multiple timepoints up to 24 hours postdose on Days 1 and 14
|
Area under the plasma drug concentration-time curve (AUC) from time zero to the end of dosing interval
|
predose and multiple timepoints up to 24 hours postdose on Days 1 and 14
|
Pharmacokinetics: Cmax
Time Frame: predose and multiple timepoints up to 24 and 72 hours postdose on Days 1 and 14, respectively
|
Maximum plasma concentration of ITI-333 and its metabolites over a dosing interval
|
predose and multiple timepoints up to 24 and 72 hours postdose on Days 1 and 14, respectively
|
Pharmacokinetics: Tmax
Time Frame: predose and multiple timepoints up to 24 and 72 hours postdose on Days 1 and 14, respectively
|
Time of maximum plasma concentration of ITI-333 and its metabolites over a dosing interval
|
predose and multiple timepoints up to 24 and 72 hours postdose on Days 1 and 14, respectively
|
Change from baseline in systolic and diastolic blood pressure
Time Frame: Up to Day 24
|
Up to Day 24
|
|
Change from baseline in SpO2
Time Frame: Up to Day 24
|
Up to Day 24
|
|
Change from baseline in ECG QT interval
Time Frame: Up to Day 24
|
Up to Day 24
|
|
Change from baseline in aspartate aminotransferase
Time Frame: Up to Day 24
|
Up to Day 24
|
|
Change from baseline in alanine aminotransferase
Time Frame: Up to Day 24
|
Up to Day 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 18, 2023
Primary Completion (Anticipated)
September 1, 2023
Study Completion (Anticipated)
September 1, 2023
Study Registration Dates
First Submitted
February 7, 2023
First Submitted That Met QC Criteria
February 7, 2023
First Posted (Actual)
February 16, 2023
Study Record Updates
Last Update Posted (Actual)
March 3, 2023
Last Update Submitted That Met QC Criteria
March 2, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- ITI-333-002
- 1UG3DA047699-02 (U.S. NIH Grant/Contract: National Institute on Drug Abuse (NIDA))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States